Among the biologicals available for the treatment of patients with CRS in Brazil, dupilumab (IL-4 and IL-13 inhibitor) is the alternative that has shown the greatest efficacy in improving olfactory function. This evidence concerns the gene IL13 and congenital rubella syndrome.